NCT01272154

Brief Summary

Purpose \- Objective : Sensorimotor adaptation allows the modification of the motor command taking into account the errors detected during execution of prior movements. It involves a large cortico-subcortical network. Isolated lesions of this network do not systematically alter sensorimotor adaptation except for cerebellar lesions. The cerebellum is thus a key structure for sensorimotor adaptation. However, the link between cerebellar and the cortical plasticity underlying sensorimotor adaptation remain unknown. Alteration of sensorimotor adaptation is associated with dystonia but it is unclear whether it is a cause or consequence of dystonia. It has been hypothesized that the abnormal plasticity observed in dystonia could account for the associated alteration of sensorimotor adaptation. Classically, basal ganglia dysfunction is considered to be crucial for dystonia pathogenesis. However, recent studies suggest that the involvement of the cerebellum may also be important in this setting. In primary dystonia, imaging studies showed abnormal cerebellar activation during sensorimotor adaptation tasks and neurophysiological studies demonstrated a decrease of cerebellar output. The aim of this study is to investigate the role of the cerebellum in the cortical plasticity underlying sensorimotor adaptation both in healthy subjects (normal plasticity) and in dystonic patients (abnormal plasticity). \- Methods: Paired associative stimulation PAS consists in repetitive pairing of a peripheral nerve and a cortical stimulation. This kind of stimulation has been designed to induce artificial plasticity that can be easily measured. This PAS induced sensorimotor plasticity is exacerbated and has lost its topographical specificity in dystonic patients.TMS using trains of TMS pulses (rTMS) can be applied on the cerebellum to modulate its output. We will test the effect of rTMS induced modulation (cTBS- inhibitory, iTBS-excitatory, sham) of the cerebellar output on PAS induced plasticity in patients with dystonia and healthy control. We will also assess the acute effect of the rTMS induced modulation of the cerebellar output on the dystonic symptoms and on the performance at a validated sensorimotor adaptation task. This will be done by double blind post-hoc scoring of the dystonia (BFM or TWSTRS) on standardized videorecording and measurement of the performance at the task after each rTMS session (cTBS, iTBS, sham). Finally, we will assess the variation of PAS effect on other parameters reflecting cortical excitability after each rTMS session (cTBS, iTBS, sham).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2011

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2011

Completed
4 days until next milestone

First Submitted

Initial submission to the registry

January 5, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 7, 2011

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 24, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 24, 2012

Completed
Last Updated

September 4, 2025

Status Verified

January 1, 2025

Enrollment Period

1.8 years

First QC Date

January 5, 2011

Last Update Submit

August 27, 2025

Conditions

Keywords

CerebellumCortical plasticitySensorimotor adaptationDystoniaCerebral PalsyTranscranial Magnetic Stimulationand

Outcome Measures

Primary Outcomes (1)

  • Comparison of MEP0/MEP10 and MEP0/MEP30 values obtained after sham, cRTBS or iTBS of the cerebellum.

    The effect of rTMS induced modulation of the cerebellar output on the PAS induced plasticity will be assessed by measurement of the size variation of a 1mV test motor evoked potential (which reflect cortical excitability) before (MEP0) and 10 and 30 minutes (MEP10 and MEP30) after PAS. The primary outcome measure will be the comparison of MEP0/MEP10 and MEP0/MEP30 values obtained after sham, cRTBS or iTBS of the cerebellum.

    6 weeks

Secondary Outcomes (3)

  • Variation of the appropriate dystonic clinical score (depending on the type of dystonia) after each rTMS session (cTBS, iTBS, sham).

    6 weeks

  • Measurement of number of errors, mean time to reach the target after each rTMS session (cTBS, iTBS, sham).

    6 weeks

  • Measurement of the variation of the motor threshold, intracortical inhibition and intracortical facilitation after each rTMS session (cTBS, iTBS, sham).

    6 weeks

Study Arms (4)

Primary cervical dystonia Patients

EXPERIMENTAL
Other: Transcranial magnetic stimulation

Primary upperlimb Dystonia Patients

EXPERIMENTAL
Other: Transcranial magnetic stimulation

Secondary Cervical or Upperlimb Dystonia due to cerebral palsy

EXPERIMENTAL
Other: Transcranial magnetic stimulation

Healthy volunteers

OTHER
Other: Transcranial magnetic stimulation

Interventions

Transcranial magnetic stimulation (PAS and rTMS)

Healthy volunteersPrimary cervical dystonia PatientsPrimary upperlimb Dystonia PatientsSecondary Cervical or Upperlimb Dystonia due to cerebral palsy

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • All subjects
  • Age \>18 years and \< 70 years
  • Normal physical and neurological examination, except for dystonia (when present)
  • No treatment with botulinum toxin during the last three months
  • No treatment altering the cortical excitability
  • Agreement to use a medically acceptable method of contraception throughout the study for female of childbearing potential
  • Primary focal dystonia group
  • Patients with cervical and/or upper limb dystonia
  • No cause of secondary dystonia
  • Secondary dystonia group
  • Cervical dystonia and/or upper limb dystonia History of perinatal anoxia

You may not qualify if:

  • MMS ≤ 24/30
  • Current neurological or psychiatric illness other than dystonia.
  • Individual who is on medication which is known to lower seizure threshold (see lists above), or who has a pacemaker, an implanted medical pump, a metal plate, a metal plate or metal object in the skull or eye (for example after brain surgery) will be excluded
  • Uncontrollable medical problems not related to dystonia such as; cardiopulmonary disease, severe rheumatoid arthritis, active joint deformity of arthritic origin, active cancer, or renal disease
  • Previous history of seizure(s) or current active epilepsy
  • Pregnancy, breast feeding women and women who are of childbearing age and not practicing adequate birth control.
  • Patients legally protected
  • Patients who are not enrolled at social security

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hpôpital Pitié Sapétrière - U 975 Plate forme " Pole Exploration de l'homme : Gait, Equilibrium, Posture, and Movement "

Paris, 75013, France

Location

Related Publications (1)

  • Hubsch C, Roze E, Popa T, Russo M, Balachandran A, Pradeep S, Mueller F, Brochard V, Quartarone A, Degos B, Vidailhet M, Kishore A, Meunier S. Defective cerebellar control of cortical plasticity in writer's cramp. Brain. 2013 Jul;136(Pt 7):2050-62. doi: 10.1093/brain/awt147.

    PMID: 23801734BACKGROUND

MeSH Terms

Conditions

DystoniaCerebral Palsy

Interventions

Transcranial Magnetic Stimulation

Condition Hierarchy (Ancestors)

DyskinesiasNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsBrain Damage, ChronicBrain DiseasesCentral Nervous System Diseases

Intervention Hierarchy (Ancestors)

Magnetic Field TherapyTherapeutics

Study Officials

  • Emmanuel Roze, MD, PhD

    Institut National de la Santé Et de la Recherche Médicale, France

    STUDY DIRECTOR
  • Asha Kishore, MD

    Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST)

    PRINCIPAL INVESTIGATOR
  • Margherita Russo, MD

    Policlinico G . Martino

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 5, 2011

First Posted

January 7, 2011

Study Start

January 1, 2011

Primary Completion

October 24, 2012

Study Completion

October 24, 2012

Last Updated

September 4, 2025

Record last verified: 2025-01

Locations